What are Some Notable Outcomes from Previous ASCO Annual Meetings?
Several significant advancements in oncology have been announced at past ASCO Annual Meetings. For instance, the introduction of Pembrolizumab (Keytruda), an immunotherapy drug, was a landmark moment that has since revolutionized the treatment of various cancers. The conference has also seen critical discussions on the use of liquid biopsies for early cancer detection and monitoring. Additionally, the meeting has highlighted the success of combination therapies, such as using PARP inhibitors in conjunction with other treatments for more effective cancer control.
